Prelude Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Prelude Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$299K	Buy	+5,474	New	+$289K	0.02%	779
2025 Q1	–	Sell	-15,000	Closed	-$590K	–	1252
2024 Q4	$590K	Buy	+15,000	New	+$708K	0.04%	540
2021 Q4	–	Sell	-2,117	Closed	-$185K	–	2004
2021 Q3	$237K	Buy	2,117 +2	+0.1%	+$251	0.01%	1264
2021 Q2	$342K	Buy	+2,115	New	+$257K	0.01%	1140
2020 Q4	–	Sell	-1,537	Closed	-$129K	–	1396
2020 Q3	$129K	Sell	1,537 -3,413	-69%	-$303K	0.01%	820
2020 Q2	$364K	Buy	+4,950	New	+$289K	0.02%	566
2019 Q3	–	Sell	-7,446	Closed	-$351K	–	1759
2019 Q2	$351K	Buy	+7,446	New	+$298K	0.02%	566
2018 Q3	–	Sell	-5,078	Closed	-$298K	–	1767
2018 Q2	$298K	Sell	5,078 -6,053	-54%	-$345K	0.02%	670
2018 Q1	$509K	Sell	11,131 -13,975	-56%	-$577K	0.04%	439
2017 Q4	$589K	Buy	+25,106	New	+$477K	0.05%	376

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Prelude Capital Management's CRSP Position: Q2 2026 in Review

Prelude Capital Management opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 5,474 shares worth $299K. The stake represents 0.02% of the portfolio and ranks #779 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in CRSP as recently as Q4 2024.

Prelude Capital Management first reported a position in CRSP in Q4 2017 and has held it in 10 quarters since. The position peaked at $590K in Q4 2024. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Prelude Capital Management held 5,474 shares of CRISPR Therapeutics worth $299K as of Q2 2026.
CRISPR Therapeutics was a new Prelude Capital Management position in Q2 2026.
CRISPR Therapeutics made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #779 holding.
Prelude Capital Management first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 10 quarters since.
Prelude Capital Management's CRISPR Therapeutics position peaked at $590K in Q4 2024.
524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.